摘要
非小细胞肺癌是最常见和死亡率最高的癌症之一,由于缺乏疾病早期生存率的研究,直至21世纪辅助化疗才引起大家的关注。2004年起多个临床试验证实,Ⅱ期和Ⅲ期患者可从辅助化疗中明显获益,而ⅠB期患者是否接受辅助化疗仍有争议。近几年,表皮生长因子受体是肿瘤学药物研发的一个重要靶点。表皮生长因子受体的小分子抑制剂成为目前非小细胞肺癌靶向治疗的热点。
Of all cancers, non-small cell lung cancer （NSCLC） is one of the most commonly diagnosed and deadliest. With a dismissal survival rate even in the early stages of disease, investigations of adjuvant therapy have not had much impact until the 21st century. Starting in 2004, several randomized trials have shown significant improvements in survival treating patients with stage 11 and m disease. Adjuvant chemotherapy remains controversial in patients with stage I B disease, in which most trims have not demonstrated a survival advantage. Epidermal growth factor receptor （EGFR） is a major target therapy. The EGFR tyrosine kinase inhibitors, Gefitinib （Iressa） and Erlotinib （Tarceva）, are two prospective agents towards NSCLC.
出处
《循证医学》
CSCD
2013年第3期185-188,共4页
The Journal of Evidence-Based Medicine
关键词
非小细胞肺癌
术后辅助治疗
热点
non-small cell lung cancer
adjuvant chemotherapy after completely resection
hotspot
